Chantell buys MAA 73.13: PHARMA TWO B EXPANDS LIST OF CLINICAL SITES ENROLLING FOR PHASE IIB STUDY OF P2B001 FOR PD TO 25
weiterlesen ... Artikel von businesswire.com: MSD, known as Merck (NYSE:MRK) in the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475 ... ...
48 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home